Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM

[1]  V. Chopra,et al.  Social Media Use in Chronic Disease: A Systematic Review and Novel Taxonomy. , 2015, The American journal of medicine.

[2]  J. Ibrahim,et al.  Web-based social media for professional medical education: Perspectives of senior stakeholders in the nursing home sector. , 2015, Nurse education today.

[3]  A. Dueck,et al.  Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls , 2015, American journal of hematology.

[4]  Jay M Bernhardt,et al.  Detecting themes of public concern: a text mining analysis of the Centers for Disease Control and Prevention's Ebola live Twitter chat. , 2015, American journal of infection control.

[5]  M. McDevitt,et al.  Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. , 2015, The New England journal of medicine.

[6]  C. Greider,et al.  Treating Myeloproliferation--On Target or Off? , 2015, The New England journal of medicine.

[7]  R. Laborde,et al.  A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. , 2015, The New England journal of medicine.

[8]  V. Arora,et al.  Criteria for social media-based scholarship in health professions education , 2015, Postgraduate Medical Journal.

[9]  N. Savage.  Scientists in the Twitterverse , 2015, Cell.

[10]  J. Landercasper,et al.  Twitter Social Media is an Effective Tool for Breast Cancer Patient Education and Support: Patient-Reported Outcomes by Survey , 2015, Journal of medical Internet research.

[11]  Brent Thoma,et al.  Creating, curating, and sharing online faculty development resources: the medical education in cases series experience. , 2015, Academic medicine : journal of the Association of American Medical Colleges.

[12]  P. F. Anderson,et al.  Disease-Specific Hashtags for Online Communication About Cancer Care. , 2016, JAMA oncology.

[13]  Nathan Lawrentschuk,et al.  The social media revolution is changing the conference experience: analytics and trends from eight international meetings , 2015, BJU international.

[14]  L. To,et al.  Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. , 2015, Blood.

[15]  S. Sutherland,et al.  Social media and medical education: Exploring the potential of Twitter as a learning tool , 2015, International review of psychiatry.

[16]  R. Mesa,et al.  Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors , 2015, Leukemia & lymphoma.

[17]  M. Schell,et al.  Prognostic and predictive values of APC and WNT pathway mutations in MSS colorectal cancers. , 2015 .

[18]  L. Balneaves,et al.  Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy , 2015, Supportive Care in Cancer.

[19]  P. Campbell,et al.  Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. , 2015, Blood.

[20]  R. Mesa,et al.  Therapy for myeloproliferative neoplasms: when, which agent, and how? , 2014, Hematology. American Society of Hematology. Education Program.

[21]  R. Mesa,et al.  Quality of Life in MPN Comes of Age as a Therapeutic Target , 2014, Current Hematologic Malignancy Reports.

[22]  C. Rooney,et al.  Social media and palliative medicine: a retrospective 2-year analysis of global Twitter data to evaluate the use of technology to communicate about issues at the end of life , 2014, BMJ Supportive & Palliative Care.

[23]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[24]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[25]  B. Phillips,et al.  The use of social-networking sites in medical education , 2013, Medical teacher.

[26]  Angela G. Fleischman,et al.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. , 2013, The New England journal of medicine.

[27]  C Haferlach,et al.  SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations , 2013, Leukemia.

[28]  M. Griesshammer,et al.  Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Roberta Spinelli,et al.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia , 2012, Nature Genetics.

[30]  M. Wasko,et al.  Understanding the Factors That Influence the Adoption and Meaningful Use of Social Media by Physicians to Share Medical Information , 2012, Journal of medical Internet research.

[31]  Robert S. Miller,et al.  Using social media in oncology for education and patient engagement. , 2012, Oncology.

[32]  Robert S. Miller,et al.  Practical guidance: the use of social media in oncology practice. , 2012, Journal of oncology practice.

[33]  Aafia Chaudhry,et al.  Trends in twitter use by physicians at the american society of clinical oncology annual meeting, 2010 and 2011. , 2012, Journal of oncology practice.

[34]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[35]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[36]  H. Kantarjian,et al.  Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.

[37]  Alan P Baptist,et al.  Social Media, Text Messaging, and Email—Preferences of Asthma Patients between 12 and 40 Years Old , 2011, The Journal of asthma : official journal of the Association for the Care of Asthma.

[38]  T. Barbui,et al.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. , 2011, Blood.

[39]  E. Larson,et al.  Dissemination of health information through social networks: twitter and antibiotics. , 2010, American journal of infection control.

[40]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[41]  G. Eysenbach,et al.  Pandemics in the Age of Twitter: Content Analysis of Tweets during the 2009 H1N1 Outbreak , 2010, PloS one.

[42]  C. Hawn.  Take two aspirin and tweet me in the morning: how Twitter, Facebook, and other social media are reshaping health care. , 2009, Health affairs.

[43]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[44]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[45]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[46]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[47]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[48]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[49]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[50]  W. Dameshek.  Editorial: Some Speculations on the Myeloproliferative Syndromes , 1951 .

[51]  H. Hasselbalch,et al.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera. , 2015, The New England journal of medicine.

[52]  Salwa Bahkali,et al.  The Role of Social Media in Promoting Women's Health Education in Saudi Arabia , 2015, ICIMTH.

[53]  N. Pemmaraju,et al.  From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[54]  M. Thompson.  Using social media to learn and communicate: it is not about the tweet. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[55]  M. Thompson.  Social media in clinical trials. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[56]  G. Demetri,et al.  A new model: physician-patient collaboration in online communities and the clinical practice of oncology. , 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[57]  J. Sloan,et al.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) , 2007, Cancer.

[58]  W. Dameshek.  Some speculations on the myeloproliferative syndromes. , 1951, Blood.